Oral heparin solution: EMIS completed enrollment in its 2,292-patient international PROTECT Phase III trial comparing its oral heparin solution given for 30 day

Emisphere Technologies Inc. (EMIS), Tarrytown, N.Y. Product: Oral heparin solution Business: Cardiovascular Therapeutic category: Thrombolysis/Thrombosis Target: Thrombin Description: Oral heparin sol...